LAS VEGAS, May 1, 2013 /PRNewswire/ -- PharmaRoth Labs,
Inc. (OTCPink: FROI) (the "Company") announced today its name
change to PharmaRoth Labs, Inc. will be effective upon the open of
trading on May 2, 2013. The
Company's common stock will begin trading under the new trading
symbol "ROTH".
"We are pleased to announce the effectiveness of our name and
trading symbol changes as they now more adequately reflects our
focus on the production, marketing, and distribution of Sucanon®,"
stated the Company's CEO Luis Lopez,
"It also completes the entry into the public marketplace and of our
reorganized company so our shareholders will be more able to
identify us."
About Sucanon®
Sucanon® is a dietary supplement containing natural ingredients. In
certain ex-US countries, it is one of only three approved drugs in
the multi-billion dollar market for a class of diabetic medications
called "insulin sensitizers". Pre-clinical and clinical studies
conducted ex-US have shown that Sucanon® and other insulin
sensitizers lower a patient's blood sugar by increasing the muscle,
fat and liver's sensitivity to the body's own naturally produced
insulin. Sucanon® has been approved for prescription sale in
China and Peru. Sucanon® is also approved as an OTC
treatment for Type-II diabetes by regulatory authorities in
Mexico. Sucanon® will be marketed
as a dietary supplement in the US.
For further information regarding Sucanon®, please visit
PharmaRoth Labs, Inc. website at www.feroindustries.com.
About PharmaRoth Labs, Inc.
PharmaRoth Labs, Inc. (OTCPink: ROTH) is focused on diabetes
prevention and treatments. The Company holds the intellectual
property and all exclusive world-wide rights related to the
production, marketing, and distribution of Sucanon®, an oral
treatment for Type-II diabetes. Sucanon® is a member of a class of
diabetic medications called insulin sensitizers. Insulin
sensitizers lower blood sugar by increasing the muscle, fat and
liver's sensitivity to insulin. Insulin sensitizers are blood sugar
normalizing or euglycemic drugs that help return the blood sugar to
the normal range without the risk of low blood sugars. PharmaRoth's
strategy is to increase awareness, acceptance, and distribution of
Sucanon® globally.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These
forward-looking statements are based on the current plans and
expectations of management and are subject to a number of
uncertainties and risks that could significantly affect the
company's current plans and expectations, as well as future results
of operations and financial condition. A more extensive listing of
risks and factors that may affect the company's business prospects
and cause actual results to differ materially from those described
in the forward-looking statements can be found in the reports and
other documents filed by the company with the Securities and
Exchange Commission. The company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
For investor relations contact:
Michael Irving - Paramount
Advisors, LLC (407) 878-5462
SOURCE PharmaRoth Labs, Inc.